Please assess the completion status of the following clinical trial:

Trial Title: 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Adolescents from ≥ 10 to ≤ 15 years of age at inclusion~2. Healthy assessed from medical history and oral temperature at inclusion~3. Vaccinated in Denmark according to the current vaccination program of 3 IPV doses in infancy and one IPV dose at pre-school age (i.e. born ≥ 1 July 1999)~4. Signed informed consent from adolescent's parent(s)/legal guardian(s)~5. Grant of authorised person's access to adolescent's medical records from adolescent's parent(s)/legal guardian(s)~6. Is willing and likely to comply with trial procedures~Exclusion Criteria:~1. Vaccinated with IPV ≤ 5 years prior to inclusion~2. Vaccinated with OPV any time prior to inclusion~3. Travelled in wild polio virus endemic region ≤ 5 years prior to inclusion~4. History of serious adverse reaction(s) after any previous vaccination~5. Known or suspected allergy to active or inactive vaccine constituents~6. Vaccinated with a live vaccine (e.g. measles, mumps, rubella, varicella, yellow fever or typhoid) ≤ 1 month prior to inclusion or during the trial. Subjects vaccinated with inactivated vaccines (e.g. tetanus, diphtheria, human papillomavirus, hepatitis A or B) are eligible for inclusion~7. Known or suspected immunodeficiency (e.g. HIV, leukaemia, lymphoma)~8. Severe uncontrolled disease (e.g. diabetes, asthma, epilepsy, heart or Crohn's disease). Patients in controlled medical treatment may be included, as assessed by the investigator~9. In treatment with systemic corticosteroids given p.o., i.v., i.m. ≤ 1 month prior to inclusion or during the trial. Subjects administered corticosteroid topically or by asthma inhalators are eligible for inclusion~10. In treatment with immune modulating products ≤ 3 months prior to inclusion or during the trial, e.g. blood products, immunoglobulins, cytostatics (e.g. methotrexate), TNF-antagonists (e.g. etanercerpt, infliximab, adalimumab, golimumab, certolizumab), or immunosuppressants (e.g. azathioprine or ciclosporin)~11. In treatment with any investigational medicinal product ≤ 3 months prior to inclusion or during the trial~12. A positive pregnancy test result at inclusion (for females who have had their first period) and/or objection to use contraception (for females who are sexually active)~13. Is unsuitable for participation in the trial or is not likely to comply with instructions as assessed by the investigator

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- 1/3 IPV-Al SSI (Type: EXPERIMENTAL): Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use
- 1/5 IPV-Al SSI (Type: EXPERIMENTAL): Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use
- 1/10 IPV-Al SSI (Type: EXPERIMENTAL): Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use
- IPV SSI (Type: ACTIVE_COMPARATOR): Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL solution for injection for intramuscular use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete